Title :

Next-Generation CAR-T Cells for HIV Cure Strategies: Dual-Specific Chimeric Antigen Receptors for Targeted Elimination of Latent Reservoirs Toward Artificial, Durable, and Adaptive Immune Surveillance

Author :

Ndenga Lumbu Barack (alias BarackEinstein97)
Independent Researcher
Kinshasa, Democratic Republic of the Congo
📧 **ndengabarack@gmail.com**
📞**(+243) 837767430**

14/01/2026

Abstract

Despite the transformative success of antiretroviral therapy (ART), HIV-1 persists as a lifelong infection due to the establishment of long-lived latent reservoirs. These reservoirs remain immunologically silent and pharmacologically inaccessible, representing the principal barrier to viral eradication. In this analysis, I explore how recent advances in cellular immunotherapy—particularly chimeric antigen receptor T (CAR-T) cell technology—offer a paradigm shift from passive viral suppression to active, programmable immune surveillance. I focus on the emergence of next-generation, dual-specific CAR-T cells engineered to recognize and eliminate HIV-infected cells, including those emerging from latency. I examine the molecular design principles, antigen selection strategies, safety engineering, and translational challenges that position CAR-T-based approaches as a cornerstone of future functional or sterilizing HIV cure strategies.

Keywords : HIV cure,CAR-T cells,Latent reservoir,Cellular immunotherapy,Synthetic immunity,Dual-specific CAR,Chimeric antigen receptor,Logic-gated CAR,Shock and Kill,Immune surveillance,HIV persistence,Immune evasion,Adoptive cell transfer,Translational medicine,Combination therapy

1. Introduction: The Architectural Failure of Natural Immunity Against HIV Persistence

The human immune system, despite its remarkable adaptability, is architecturally unequipped to eradicate HIV-1. Cytotoxic T lymphocytes (CTLs) exert strong selective pressure during acute infection, yet viral escape mutations, immune exhaustion, and anatomical sanctuary sites enable long-term persistence. Most critically, latently infected $CD4^+$ T cells express little to no viral antigen, rendering them invisible to endogenous immune surveillance. This failure is not merely quantitative; it is a fundamental design flaw in our natural defenses. I argue that CAR-T cell technology directly addresses this architectural limitation by providing a platform for synthetic immune recognition, bypassing major histocompatibility complex (MHC) dependence and enabling the detection of viral signatures that the body was never evolved to see.



Figure 1. Natural immune surveillance failure and the synthetic intervention of HIV-specific CAR-T cells.

(A) Failed natural clearance: A cytotoxic T lymphocyte (CTL, blue) fails to recognize a latently infected CD4⁺ T cell (grey) due to the absence of MHC-I presented viral peptides (red "X"). The cell harbors an integrated HIV provirus (red strand in nucleus). (B) Synthetic CAR-T recognition and killing: An engineered CAR-T cell (green) expresses a chimeric antigen receptor (CAR) that directly binds to HIV envelope proteins (Env, red spikes) on the surface of a reactivated infected cell, leading to immune synapse formation, cytotoxic granule release (yellow circles), and target cell apoptosis. Created with BioRender.com.

2. CAR-T Cell Technology: From Oncologic Revolution to Antiviral Platform

2.1 The Synthetic Immune Receptor: A Redesigned Toolkit

A chimeric antigen receptor (CAR) is a synthetic fusion protein that reprograms T cell specificity. Its canonical architecture comprises: an extracellular antigen-recognition domain (typically a single-chain variable fragment, scFv), a transmembrane domain, and one or more intracellular signaling domains (e.g., CD3ζ combined with co-stimulatory domains like CD28 or 4-1BB). Originally engineered for hematological malignancies, CAR-T cells exhibit properties that make them uniquely attractive for chronic viral infections: antigen recognition independent of MHC presentation, high and direct cytotoxic potency, and the potential for long-term persistence and memory formation. I position this technology not as a mere transplant from oncology, but as a foundational toolkit for building synthetic immunity.

3. The Rationale for CAR-T Therapy in HIV: Targeting Invisibility

HIV latency is dynamic rather than absolutely static. Low-level viral transcription, stochastic reactivation, and cell-to-cell spread generate transient windows of antigen exposure. Natural CTLs often miss these fleeting opportunities due to exhaustion or suboptimal TCR affinity. CAR-T cells, however, can be engineered to exploit these windows with superior sensitivity and sustained vigilance. The key strategic advantages I explore are: the ability to target conserved viral epitopes less prone to mutation, the immediate elimination of infected cells upon viral reactivation, and the establishment of a persistent, artificial immune patrol that maintains constant pressure on the reservoir.

4. Dual-Specific CAR-T Cells: The Strategic Evolution for a Shape-Shifting Target



Figure 2. Architecture and logic of dual-specific, next-generation CAR-T cells for HIV.

Comparative schematics of CAR designs. (A) First-generation CAR: A single-chain variable fragment (scFv, orange) targeting HIV Env, linked to CD3ζ and co-stimulatory (e.g., 4-1BB) signaling domains. (B) Tandem (OR-gate) CAR: Features two distinct scFvs (orange and blue) targeting different HIV/host antigens (e.g., Env and CD4), either of which can activate the T cell. (C) Logic-gated (AND-gate) CAR: Incorporates two separate CARs with split signaling domains. Full T cell activation requires simultaneous engagement of both target antigens (e.g., Env AND a host activation marker), maximizing specificity for genuine HIV-infected cells. Created with BioRender.com.

4.1 The Imperative for Redundant Recognition

Single-antigen targeting in HIV is a recipe for rapid immune escape. The virus's prolific mutational capacity necessitates recognition systems with built-in redundancy and logic. This is where dual-specificity becomes non-negotiable. I analyze advanced CAR designs that incorporate this principle, including: Tandem CARs (or "OR-gate" CARs) that activate upon engagement of either target antigen, Bivalent CARs with two scFvs for a single antigen to enhance avidity, and most promisingly, Logic-Gated CARs (e.g., "AND-gate" CARs) that activate fully only upon simultaneous engagement of two distinct antigens (e.g., a viral protein and a host cell marker of infection). This architectural evolution dramatically improves specificity for genuine HIV-infected cells while minimizing off-target cytotoxicity against healthy tissues.

5. The Antigen Landscape: Choosing the Targets for Synthetic Recognition

5.1 Viral Antigens: Conserved Achilles' Heels

The primary targets are HIV-1 envelope glycoproteins (gp120/gp41). However, targeting highly variable loops is futile. I focus the strategy on conserved Env regions exposed during fusion (such as the CD4-induced epitopes) or conformations specifically associated with viral rebound. The goal is to design CARs that recognize the virus in its "actionable" state.

5.2 Host-Derived Infection Markers: The Cellular Context

To enhance specificity beyond the virus alone, I examine complementary targets in the host cell. These include stable CD4–Env complexes on the surface of infected cells, cellular activation markers that may be enriched during latency reversal, and—as an area of intense investigation—unique surface signatures or stress ligands presented by cells harboring integrated provirus. Targeting a host:viral combinatorial signature is the path to true precision.

6. Engineering for Persistence and Safety: Building a Durable and Controllable Therapy

6.1 Engineering Cellular Fitness and Durability

For CAR-T cells to function as a long-term surveillance system, they must persist. I discuss key engineering strategies: deriving CAR-T products from central memory or stem-cell memory T cell subsets, incorporating cytokine signaling domains (e.g., IL-7R, IL-15) to promote homeostatic survival, and engineering resistance to exhaustion through the modulation of intrinsic checkpoint pathways (e.g., dominant-negative PD-1).

6.2 Integrating Fail-Safe Mechanisms

The potency of CAR-T cells demands robust safety controls. I evaluate the incorporation of suicide switches (e.g., inducible caspase-9), the tuning of signaling strength to avoid cytokine release syndrome, and novel "on-switch" strategies where CAR activity is dependent on the administration of a small molecule, providing spatial and temporal control.

7. CAR-T Cells in the Curative Ecosystem: Enabling Reservoir Clearance

I contend that CAR-T therapy alone is unlikely to eliminate deeply latent cells that express no antigen. Its true power is unlocked in rational combination. When paired with latency-reversing agents (LRAs), CAR-T cells become the precise and potent "kill" arm of a modern "Shock and Kill" strategy. Furthermore, combination with immune checkpoint blockade can rejuvenate both engineered and endogenous immunity, and coupling with a therapeutic vaccine could drive the in vivo expansion of HIV-specific CAR-T cells. This synergetic logic positions CAR-T not as a standalone cure, but as the central effector module within a multi-component curative regimen.



Figure 3. Integration of CAR-T cells into a combinatorial "Shock and Kill" curative strategy.

A sequential therapeutic workflow. Step 1 (Shock): Administration of a latency-reversing agent (LRA, yellow triangle) to reactivate HIV transcription in a latent reservoir cell. Step 2 (Antigen Exposure): The reactivated cell expresses HIV Env proteins (red spikes) on its surface. Step 3 (Kill): Pre-infused dual-specific CAR-T cells (green) recognize the Env signature, form an immune synapse, and eliminate the target cell, preventing viral spread. Step 4 (Surveillance): A durable memory CAR-T cell population persists, providing long-term adaptive immune surveillance against viral rebound. Created with BioRender.com.

8. Translational Realities: Challenges and the Imperative of Equity

The path from concept to clinic is fraught with barriers. I address the manufacturing complexity and cost of autologous cell therapies, the profound challenge of scalability for low- and middle-income countries—which bear the greatest HIV burden—and the need for frameworks for long-term safety monitoring of persistent engineered cells. For any technology aiming at an HIV cure, equitable access is not an afterthought; it is a core metric of success and must be integrated into development roadmaps from the outset.

9. A Generalizable Platform: Beyond HIV

The implications of this work extend far beyond HIV. The framework for designing synthetic, logic-gated immune receptors against persistent antigens is directly applicable to other intractable challenges: chronic hepatitis **B** infection, control of persistent herpesviruses, and the targeting of virus-associated cancers. The HIV cure effort is thus pioneering a generalizable platform for programmable immunity.

10. Conclusion: The Dawn of Artificial Immune Surveillance

Next-generation, dual-specific CAR-T cells represent more than a new therapy; they redefine the very concept of an immune intervention. They shift the paradigm from transient pharmaceutical suppression to the installation of a living, adaptive, and programmable surveillance system. While the translational challenges are significant, this approach marks a decisive leap from simply managing HIV to architecting a biological solution designed to outlast and outmaneuver it. In this vision, the path to a functional HIV cure is paved not only by silencing or eliminating the virus, but by rebuilding the immune sentry that stands guard against it.

References

Deeks, S. G., et al. Nature Medicine (2021).

Zhen, A., & Kitchen, S. G. Frontiers in Immunology (2019).

Liu, B., et al. Cell (2022).

Maldini, C. R., et al. Science

Translational Medicine (2020).

June, C. H., et al. Science (2018).

Bibliographical references for Ndenga Lumbu Barack

Chuck, C., Robinson, J., & Ndenga, B. (2025). Bio-Adaptive Quantum Error Correction: Immune-Inspired Priors Enable 22–65% Overhead Reduction in Surface-Code Decoding (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17684948

Maman Moussa Maman, M., & Ndenga, B. (2025). Nutritional and Nutraceutical Valorization of Edible Grasshoppers from Niger: A Multi-Omics Characterization Integrated with Artificial Intelligence for Personalized Food Formulations (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17841603

Maman Moussa Maman, M., & Ndenga, B. (2025). Mathematical and Nutritional Modeling for Predicting the Effectiveness of Malaria Preventive Interventions: An Integrated Epidemiological Framework for Population-Level Risk and Response Optimization (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17886414

Maman Moussa Maman, M., & Ndenga, B. (2025). Beyond Body Mass Index: Development of the Adjusted Central Corpulence Index (ICCA) Integrating Age, Sex, and Abdominal Adiposity for Cardiometabolic Risk Assessment (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17955316

Maman Moussa Maman, M., Ndenga, B., SORE, I., Makiasi hambadiana, Y., & SCHOUNA MENI, C. (2025). Integrative Modulation of Telomeric Dynamics and Cellular Senescence through Nutrition, Phyto-Pharmacological Compounds, Translational Medicine, Artificial Intelligence, and Quantum Simulation. (Version V1). Zenodo. https://doi.org/10.5281/zenodo.18075291

Maman Moussa Maman, M., Ndenga, B., SORE, I., Makiasi hambadiana, Y., SCHOUNA MENI, C., & Fatou, D. (2026). Complementary Mechanisms of Action and Potential Synergies Between Nutrition, Physical Activity, and Phytotherapy in Cardiometabolic Prevention : A Narrative Review and Theoretical Framework for the African Context (Version V1). Zenodo. https://doi.org/10.5281/zenodo.18116505

Maman Moussa Maman, M., Ndenga, B., SORE, I., Makiasi hambadiana, Y., SCHOUNA MENI, C., & Fatou, D. (2026). Development and Validation of ICCA-O (Optimized Adjusted Central Adiposity Index): A Composite Cardio-Metabolic Risk Indicator Integrating BMI, WHR, WtHR, ABSI, and BAI (Version V1). Zenodo. https://doi.org/10.5281/zenodo.18119723

Maman Moussa Maman, M., & Ndenga, B. (2025). Artificial Intelligence–Driven Personalized Optimization of Antimalarial Therapies Through the Integration of Nutrition,

Phytotherapy, and Pharmacology: A Multi-Factor Predictive Modeling Framework (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17861029

Maman Moussa Maman, M., & Ndenga, B. (2025). AI-Enhanced Biochemical Discovery and Optimization of Antimalarial Compounds from Indigenous Medicinal Plants: An Integrative Framework for Data-Driven Natural Product Drug Development (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17868086

Makiasi Hambadiana, Y., & Ndenga, B. (2025). Development of a Nutrient-Dense Infant Porridge Based on Local Ingredients in Kinshasa (DRC): The Hamba's Society Model (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17089147

Makiasi Hambadiana, Y., & Ndenga, B. (2025). Prostate-Protective Bioactivity of Cucurbita maxima Seeds: Molecular Pathways, Endocrine Regulation, and Clinical Relevance (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17880798

Makiasi hambadiana, Y., & Ndenga, B. (2025). Biocatalytic and Cytoprotective Role of the Zinc–L–Carnosine Complex in Gastric Mucosal Regeneration (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17410492

Makiasi Hambadiana, Y., & Ndenga, B. (2025). Functional and Preventive Potential of Cucurbita maxima as a Nutritional Therapeutic Agent. (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17763294

Ndenga, B. (2025). Information-Driven Order Formation in Natural and Artificial Systems (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17970157

Ndenga, B. (2026). Immuno-Engineering of Hematopoietic Stem Cells for Durable Immune Resistance to HIV: From the CCR5Δ32 Mutation to Autologous Gene Therapies Mediated by Lentiviral Vectors (Version V1). Zenodo. https://doi.org/10.5281/zenodo.18203370

Ndenga, B. (2025). Reading and Transcription of a Tetra-Stranded Genetic Polymer : Decoding Channels, Controlled Ambiguities, and the Formal Definition of the Q-Code (Version V1). Zenodo. https://doi.org/10.5281/zenodo.18068961

Ndenga, B. (2025). Information-Theoretic Capacity of a Tetra-Stranded Hereditary Polymer : Effective Alphabets, Encoding Density, and Readout Constraints in Q-DNA (Version V1). Zenodo. https://doi.org/10.5281/zenodo.18056935

Ndenga, B. (2025). Replication of a Tetra-Stranded Genome : Mechanistic Scenarios and Minimal Enzymatic Constraints for Q-DNA (Version V1). Zenodo. https://doi.org/10.5281/zenodo.18064787

Ndenga, B. (2025). Catalogue of Tetra-Stranded Helical Architectures: Classes, Topological Invariants, and Structural Transitions (Version V1). Zenodo. https://doi.org/10.5281/zenodo.18028731

Ndenga, B. (2025). Q↔D Kinetics: Nucleation, Propagation, and Kinetic Traps in a Tetra-Stranded Hereditary Polymer (Version V1). Zenodo. https://doi.org/10.5281/zenodo.18054763

Ndenga, B. (2026). Programmable Nanomedicine and Multifunctional Vectors for the Selective Targeting of HIV-1 Reservoirs: Toward a Next-Generation Shock & Kill Strategy (Version V1). Zenodo. https://doi.org/10.5281/zenodo.18177087

Ndenga, B. (2025). Thermodynamics of a Tetra-Stranded Genome: Stability, Thresholds, and Entropic Constraints (Version V1). Zenodo. https://doi.org/10.5281/zenodo.18036881

Ndenga, B. (2025). Q-DNA: A Formal Definition of a Canonical Tetra-Stranded Hereditary Polymer Beyond the Double Helix (Version V1). Zenodo. https://doi.org/10.5281/zenodo.18015887

Ndenga, B. (2025). Quantum π in Biomolecular Dynamics: Proteins as Nano-Quantum Fluids (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17795878

Ndenga, B. (2025). Evolvability and Selection in a Tetra-Stranded Genome : Robustness, Modularity, and Adaptive Dynamics in Q-DNA (Version V1). Zenodo. https://doi.org/10.5281/zenodo.18071359

Ndenga, B., & Sharma, H. (2025). Information Against Entropy: Toward a Governing Principle of Organization in Complex Systems (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17944808

Ndenga, B., & Himanshi, . sharma . (2025). Microcapsule-Enabled Self-Healing Silicon Anodes for Next-Generation Lithium-Ion Batteries: A Conceptual Design, Materials Framework, and Technical Feasibility Study (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17981741

Ndenga, B. (2025). Rigidity, Torsion, and Mechanical Response of a Tetra-Stranded Genome : A Unified Theoretical and Experimental Framework for Q-DNA Elasticity (Version V1). Zenodo. https://doi.org/10.5281/zenodo.18052220

Ndenga, B. (2025). Mutation Landscape and Error Correction in Q-DNA : Correlated Errors, Structural Redundancy, and Topological Self-Correction in a Tetra-Stranded Hereditary Polymer (Version V1). Zenodo. https://doi.org/10.5281/zenodo.18060921

Ndenga, B. (2025). Legume-Derived Anti-Angiogenic Networks Targeting Renal Cell Carcinoma: Mechanistic Insights into Polyphenol–Saponin–Fiber Bioactive Complexes from Phaseolus vulgaris (Version V1). Zenodo. https://doi.org/10.5281/zenodo.18005392

Ndenga, B. (2025). Climate-Adaptive Batteries: Passive Thermal Regulation of Lithium-Ion Batteries Using Thermochromic Functional Surface Films (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17999867

Ndenga, B. (2025). Atomistic Stability of Q-DNA: Molecular Dynamics Simulations and Structural Persistence Criteria (Version V1). Zenodo. https://doi.org/10.5281/zenodo.18047941

Ndenga, B. (2025). Four-Strand Pairing Beyond Watson–Crick: Interaction Hypergraphs, Controlled Degeneracy, and Sequence Constraints (Version V1). Zenodo. https://doi.org/10.5281/zenodo.18040162

Ndenga, B. (2025). Information, Entropy, and System Dynamics: A Unified Framework Toward an Extended Thermodynamic Principle of Organization Across Physical, Biological, and Computational Systems (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17924903

Ndenga, B. (2025). The Informational Foundations of Organization in Physical and Biological Systems : Toward an Extended Thermodynamic Principle of Self-Organization (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17917388

Ndenga, B. (2025). On Organizational Efficiency and the Limits of Non-Equilibrium Thermodynamics Toward an Information-Centered Theory of Organization (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17931806

Ndenga, B. (2025). R-Law AI: A Thermodynamic Information–Entropy Framework for Self-Organizing Neural Networks Based on the IOE Principle (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17860353

Ndenga, B. (2025). The Extended Fifth Law of Thermodynamics: Establishing Information as a Fundamental Physical Quantity (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17904738

Ndenga, B. (2025). THE PRINCIPLE OF INFORMED ORGANIZATIONAL EFFICIENCY : A Comprehensive Foundational Framework for an Extended Fifth Law of Thermodynamics (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17848436

Ndenga, B. (2025). Nano-Turbulence in Biological Systems: A New Paradigm (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17803565

Ndenga, B. (2025). Schrödinger–Navier–Stokes–π Unified Computational Framework : A Unified Theoretical and Numerical Architecture for Quantum-Coherent Fluid Dynamics Across Physical and Biological Scales (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17832286

Ndenga, B. (2025). The Complete Solution to the Glass Transition: A Unified Energy–Topology Landscape (ETL) Framework (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17741451

Ndenga, B. (2025). Quantum-Fluid Interpretation of Enzymatic Tunnels and Energy Transport (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17822207

Ndenga, B. (2025). Schrödinger–Navier–Stokes–Quantum-π: A Unified Model and Hybrid Numerical Method for Quantum Fluids with π-Phase Structure (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17770899

Ndenga, B. (2025). Quantum π-Unification II: Definition, Mathematical Structure, and Foundational Properties of the Quantum π for Molecular Systems (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17716546

Ndenga, B. (2025). Electrostatics of a Tetra-Stranded Polymer: Ionic Condensation and Nonlinear Screening (Version V1). Zenodo. https://doi.org/10.5281/zenodo.18044219

Ndenga, B. (2025). H-ImmQπDecoder v2.0: A Bio-Inspired Quantum Error Decoder Integrating Immune Adaptation, Quantum-π Phase Control, and Quantum Metabolism (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17782652

Ndenga, B. (2025). The Octet Rule Revisited: A Quantum-Continuum Framework for Chemical Bonding (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17703765

Ndenga, B. (2025). Foundations of Quantum-π in Molecular Systems: A Fundamental Descriptor of Delocalization, Electronic Structure, and Molecular Stability. Zenodo. https://doi.org/10.5281/zenodo.17692965

Ndenga, B. (2025). Quantum π-Index in Advanced Materials: Predictive Framework for Nanostructures, Functional Polymers, and Superconducting States (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17662004

Ndenga, B. (2025). Q-Synapse: A Hybrid Quantum–AI Platform for Tumor State Classification Using Real Genomic Data (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17655039

Ndenga, B. (2025). Crystal-Guided AI Phototherapy for Personalized Oncology (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17398364

Ndenga, B. (2025). Quantum π-Driven Predictive Chemistry: Applications to Reactivity, Electronic Structure, and Simulation-Based Forecasting (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17654148

Ndenga, B. (2025). Numerical Solution of the Navier-Stokes Equations in 3D Using the Finite Volume Method: Application to the Millennium Problem. Zenodo. https://doi.org/10.5281/zenodo.15531853

Ndenga, B. (2025). Electronless Nuclear Matter: Magnetic Confinement and Bonding of Bare Nuclei in Extreme Fields (Version V1). Zenodo. https://doi.org/10.5281/zenodo.15764734

Ndenga, B., & Ndenga, B. (2025). AutoEvoChem V2.0 – A Smart Molecular Simulation & Synergy AI Toolkit for Computational Chemists and Biopharma Researchers. Zenodo. https://doi.org/10.5281/zenodo.15774

Ndenga, B. (2025). NanoChemicalDisc RDC-1000: A Novel Molecular Approach to Low-Cost Data Storage Using Colorimetric Encoding. Zenodo. https://doi.org/10.5281/zenodo.15871728

Ndenga, B. (2025). Autoevolving Nanodisk with Unlimited Memory: A Bioinspired and Quantum-Spiritual Approach (Version V1). Zenodo. https://doi.org/10.5281/zenodo.16569012

Ndenga, B. (2025). Self-Adaptive Photosynthetic Quantum Crystal: A Bioinspired Innovation for Intelligent Light Harvesting and Energy Conversion (Version V1). Zenodo. https://doi.org/10.5281/zenodo.16585048

Ndenga, B. (2025). Quantum-Nuclear DNA Computing: Using Nucleotide Spin States as Biological Quantum Bits for Molecular Calculations (Version V1). Zenodo. https://doi.org/10.5281/zenodo.16891194

Ndenga, B. (2025). BECChem: Self-Evolving Chemical AI for Advanced Molecular Analysis (Version V1). Zenodo. https://doi.org/10.5281/zenodo.16934328

Ndenga, B. (2025). Nuclear Matter Without Electrons: The Magneto-Nuclear Periodic Table (MNPT) and the Taxonomy of Nucleomorphs (Version V1). Zenodo. https://doi.org/10.5281/zenodo.16955871

Ndenga, B. (2025). Design of Multi-Target Hybrid Molecules for Synergistic Therapy of Malaria and Human African Trypanosomiasis (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17074442

Ndenga, B. (2025). Biological Neural Calculator Using Plant-Based Electromagnetic Responses (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17094316

Ndenga, B. (2025). Title: Molecular Wormhole Chemistry: Electronic Non-Locality Induced by Wormhole-Like Geometries in Conjugated Molecular Systems (Version V1). Zenodo. https://doi.org/10.5281/zenod.17114802

Ndenga, B. (2025). Towards a Unified AI-Driven Quantum Framework: Beyond Density Functional Theory for 3D Materials. https://doi.org/10.5281/zenodo.17148362

Ndenga, B. (2025). A Knot-Theoretic Approach to Turbulence: Toward Predictive Invariants in 3D Fluid Flows (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17172786

Ndenga, B. (2025). Towards a Unified Field Theory of Chemistry: Bridging Quantum, Organic, and Biochemical Reactions through a Single Formalism (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17217047

Ndenga, B. (2025). Vacuum Metabolism: A Theoretical Framework for Biological Exploitation of Quantum Zero-Point Energy (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17261682

Ndenga, B. (2025). The Darwin Limit: Mathematical Constraints on the Speed of Biological Evolution (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17280016

Ndenga, B. (2025). Integrating AI, Photonics, and Molecular Modeling: The Future of Precision Medicine (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17295049

Ndenga, B. (2025). Photonics + AI: Revolutionizing In Silico Drug Design (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17315749

Ndenga, B. (2025). Photonics and AI in Computational Oncology: Accelerating the Design of Next-Generation Cancer Therapies (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17341571

Ndenga, B. (2025). AI-Driven Light-Spectrum Optimization for Photonic Drug Discovery (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17360624

Ndenga, B. (2025). Photon-Enhanced AI Platforms for Multimodal Therapeutics (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17373765

Ndenga, B. (2025). AI-Optimized Photon-Assisted Molecular Docking for Rapid Drug Discovery (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17416035

Ndenga, B. (2025). Photonics + AI for Real-Time Molecular Interaction Mapping (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17435502

Ndenga, B. (2025). Light-Speed AI for Personalized Drug Optimization (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17456941

Ndenga, B. (2025). Introduction to the Concept of π in the Quantum World (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17509410

Ndenga, B. (2025). π in Fundamental Quantum Systems (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17532815

Ndenga, B. (2025). Spectrally-Driven Active Learning Enables Femtojoule-Efficient Discovery of Photocatalysts in Under One Hour: The LuminaFemto AI Platform (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17497652

Ndenga, B., & Ometie, C. (2025). Polyunsaturated Neuroprotectants as Adjuvant Agents: Anti-Proliferative and Membrane-Stabilizing Effects of Nuciferous Compounds from Juglans regia in Invasive Glioma Models (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17557055

Ndenga, B. (2025). The IOE Ratio: Quantifying Organizational Potential in Complex Systems (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17956802

Ndenga, B. (2025). Bio-IA Supercomputer: Concept, Design, and Implementation of an AI-Integrated Biocomputer (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17562958

Ndenga, B. (2025). π and the Quantum Structure of Probability: From Wavefunction Normalization to Statistical Distributions (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17569342

Ndenga, B. (2025). π as a Quantum Signature: Applications and Universal Implications (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17589339

Ndenga, B. (2025). Hormonal Receptor Modulation by Lipid Phytoconstituents: The Role of Monounsaturated Fatty Acids and Folate Derivatives from Persea americana in Endometrial Carcinogenesis Prevention (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17595231

Ndenga, B. (2025). Gastro-Oncology of Ginger: A Molecular Dissection of Gingerols and Shogaols as Dual Anti-Inflammatory and Anti-Mutagenic Agents in Gastric Carcinogenesis — with AutoEvoChem V2.0 Simulation Pipeline (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17665633

Ndenga, B. (2026). Advanced Structural Vaccinology and Mosaic Nanoparticles for the Rational Induction of Broadly Neutralizing Antibodies Against HIV: Circumventing the Extreme Hypervariability of the Viral Envelope (Version V1). Zenodo. https://doi.org/10.5281/zenodo.18216577

Ndenga, B. (2025). π and Delocalized Electrons: A Quantum-Chemical Reassessment of Coherence, Stability, and Molecular Structure (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17613175

Ndenga, B. (2025). Toward a Quantum Definition of π in Molecular Systems: Original Formula, Mathematical Framework, and Foundational Implications (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17633204

Ndenga, B. (2025). Innovative Limonoid-Based Targeted Therapy: Citrus-Derived Compounds for Selective Apoptosis and Cell-Cycle Control in Estrogen-Dependent Breast Cancer (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17619732

Ndenga, B. (2026). The HIV Paradox: Acquired Immunodeficiency, Latent Reservoirs, and Mechanisms of Viral Persistence Why Antiretroviral Therapies Fail to Achieve a Curative Outcome (Version V1). Zenodo. https://doi.org/10.5281/zenodo.18148991

Ndenga, B. (2025). Carotenoid Signaling and Mitochondrial Protection at the Crossroads of Cardio-Oncology: Lycopene as a Dual Modulator of Cardiovascular and Cancer Risk (Version V1). Zenodo. https://doi.org/10.5281/zenodo.18009606

Ndenga, B. (2025). Resolving Nanoscale Reaction Kinetics: A Unified Framework from Classical Chemistry to Quantum Collectivity (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17754650

Ndenga, B. (2025). Q-BattX Cloud™: A Quantum-AI–Driven Cloud Platform for Next-Generation Energy Storage Simulation and Optimization (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17643284

Ndenga, B. (2025). Correlated Quantum Matter Beyond Band Theory: A Continuum-Interaction Formalism for Strongly Coupled Electrons (Version V1). Zenodo. https://doi.org/10.5281/zenodo.

MULONSO, H., Ndenga, B., & MATAMBA MPINGIJA, C. (2025). Techniques Used for Analyzing Fatty Acids in Food (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17417545

MULONSO, H., Ndenga, B., & Kabena Ilunga, M. (2025). Antioxidant Potential of Cymbopogon citratus Leaf Extracts in the Prevention of Oxidative Stress Involved in Cancer (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17429758

MULONSO, H., Ndenga, B., & MATAMBA MPINGIJA, C. (2025). Metabolomic Study of Bioactive Compounds in Cymbopogon citratus: Identification of Antioxidant Molecules with Potential Anticancer Activity (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17458790

MULONSO, H., & Ndenga, B. (2025). Phytochemical Analysis and Free Radical Scavenging Activity of Methanolic and Chloroformic Extracts of Cymbopogon citratus: Implications for Cancer Chemoprevention (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17489746

MULONSO, H., & Ndenga, B. (2025). Therapeutic Perspectives of Natural Compounds from Cymbopogon citratus in the Management of Oxidative Stress Associated with Cancer (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17504613

MULONSO, H., & Ndenga, B. (2025). Evaluation of the Anti-inflammatory and Antioxidant Effects of Cymbopogon citratus as Adjuvant Agents in Cancer Therapy (Version V1). Zenodo. https://doi.org/10.5281/zenodo.17518166

MULONSO, H., & Ndenga, B. (2025). Contribution of Enzymatic and Non-Enzymatic Antioxidants from Cymbopogon citratus to Cellular Protection Against Oxidative Damage in Cancer (Version V1). Zenodo. https://doi.org/10.5281/zenodo.